Anti-HIgG(Fc)-C-PBD ADC (CAT#: ADC-AA-059)

A: The cleavable linker in the Anti-HIgG(Fc)-C-PBD ADC is designed to be stable in extracellular fluids, ensuring that the cytotoxic agent, PBD, remains attached during circulation. Once internalized into a target cell via endocytosis, the linker is cleaved by the enzyme cathepsin within the endosome, releasing PBD to exert its cytotoxic effects by binding to the DNA minor groove and cross-linking DNA.

A: This ADC targets cancer cells expressing human IgG Fc receptors. The antibody portion binds to these receptors, triggering endocytosis of the ADC into the cell. Once inside, the linker is cleaved, releasing PBD which then interacts with DNA to inhibit cell proliferation and induce apoptosis.

A: For laboratory experiments, it is recommended to use the ADC at controlled concentrations, initially testing in vitro on cancer cell lines expressing human IgG Fc receptors. Optimal conditions, including concentration and incubation times, should be determined based on specific experimental setups and objectives.

A: The ADC minimizes off-target effects through its specific targeting mechanism-binding only to cells that express human IgG Fc receptors. The stability of the cleavable linker in extracellular fluid also prevents premature release of the cytotoxic drug, reducing potential damage to non-target cells.

A: Essential preclinical tests for the Anti-HIgG(Fc)-C-PBD ADC include toxicity studies, pharmacokinetics and pharmacodynamics assessments, and efficacy studies in relevant animal models. Additionally, testing on multiple cancer cell lines to assess the ADC's specificity and mechanism of action is crucial to ensure safety and effectiveness before proceeding to human trials.